EQ-5D in Central and Eastern Europe : 2000-2015 by Rencz, F. et al.
This is an author produced version of EQ-5D in Central and Eastern Europe : 2000-2015.
White Rose Research Online URL for this paper:
http://eprints.whiterose.ac.uk/103841/
Article:
Rencz, F., Gulacsi, L., Drummond, M.F. orcid.org/0000-0002-6126-0944 et al. (10 more 
authors) (2016) EQ-5D in Central and Eastern Europe : 2000-2015. Quality of Life 
Research. pp. 2693-2710. ISSN 1573-2649 
https://doi.org/10.1007/s11136-016-1375-6
promoting access to
White Rose research papers
eprints@whiterose.ac.uk
http://eprints.whiterose.ac.uk/
1 
 
Title page 
 
Title: EQ-5D in Central and Eastern Europe: 2000-2015 
 
Authors: 
Fanni Rencz1,2, László Gulácsi1, Michael Drummond3, Dominik Golicki4 Valentina Prevolnik 
Rupel5, Judit Simon6, Elly A. Stolk7, Valentin Brodszky1, Petra Baji1, Jakub Závada8, Guenka 
Petrova9, Alexandru Rotar10, Márta Péntek1 
1 ± &RUYLQXV8QLYHUVLW\RI%XGDSHVW'HSDUWPHQWRI+HDOWK(FRQRPLFV)ĘYiPWpU+-1093 
Budapest, Hungary 
2 ± 6HPPHOZHLV 8QLYHUVLW\ 'RFWRUDO 6FKRRO RI &OLQLFDO 0HGLFLQH hOOĘL ~W  +-1085 
Budapest, Hungary 
3 ± Centre for Health Economics, University of York, Heslington, York, YO10 5DD, UK  
4 ± Department of Experimental and Clinical Pharmacology, Medical University of Warsaw, 
Poland, ul. Banacha 1b, 02-097 Warsaw, Poland 
5 ± ,QVWLWXWHIRU(FRQRPLF5HVHDUFK.DUGHOMHYDSORãþDG/MXEOMDQD6ORYHQLD 
6 ± Department of Health Economics, Centre for Public Health, Medical University of 
Vienna, Kinderspitalgasse 15/1 1090 Vienna, Austria  
7 ± Erasmus University Rotterdam, Institute of Health Policy and Management, P.O. Box 
1738 3000 DR Rotterdam The Netherlands  
8 ± Institute of Rheumatology, Na Slupi 4, Prague, 128 00, Czech Republic  
9 ± Department of Social Pharmacy and Pharmacoeconomics, Faculty of Pharmacy, Medical 
University, Sofia, Bulgaria 
10 ± Department of Social Medicine, University of Amsterdam, Meibergdreef 9, 22660, 1100 
DD Amsterdam, The Netherlands 
 
Compliance with Ethical Standards 
 
Funding statement: None. 
 
Conflict of interest: FR, LG, MD, JS, VB, PB, JZ, GP and MP have nothing to disclose. 
DG reports grants and non-financial support from EuroQol Group, outside the submitted 
work; and he is a member of the EuroQol Group, a not-for-profit organization that develops 
and distributes instruments that assess and value health. 
2 
 
VPR is member of the EuroQol Group. 
EAS reports grants and other from EuroQol research foundation, outside the submitted work. 
AR is a salaried employee of Sanofi-Aventis Romania. The review is strictly the personal 
point of view of the author and it does not reflect the position of Sanofi-Aventis Romania. 
 
Ethical standard: No ethical approval is required because this is a systematic review.  
Informed consent: Informed consent is not required because this is a systematic review. 
 
 
Corresponding author: 
László Gulácsi M.D., Ph.D. 
Corvinus University of Budapest 
)ĘYiPWpU+-1093 Budapest, Hungary 
E-mail: laszlo.gulacsi@uni-corvinus.hu  
Phone: +36 1 482-5033 
Fax: +36 1 482-5033 
 
 
 
 
 
  
3 
 
Abstract 
 
Objective: Cost per quality-adjusted life year data are required for reimbursement decisions 
in many Central and Eastern European (CEE) countries. EQ-5D is by far the most commonly 
used instrument to generate utility values in CEE. This study aims to systematically review 
the literature on EQ-5D from eight CEE countries.  
Methods: An electronic database search was performed up to July 1, 2015 to identify original 
EQ-5D studies from the countries of interest. We analysed the use of EQ-5D with respect to 
clinical areas, methodological rigor, population norms and value sets. 
Results: We identified 143 studies providing 152 country-specific results with a total sample 
size of 81,619: Austria (n=11), Bulgaria (n=6), Czech Republic (n=18), Hungary (n=47), 
Poland (n=51), Romania (n=2), Slovakia (n=3) and Slovenia (n=14). Cardiovascular (20%), 
neurologic (16%), musculoskeletal (15%) and endocrine/nutritional/metabolic diseases (14%) 
were the most frequently studied clinical areas. Overall 112 (78%) of the studies reported EQ 
VAS results and 86 (60%) EQ-5D index scores, of which 27 (31%) did not specify the applied 
tariff. Hungary, Poland and Slovenia have population norms. Poland and Slovenia also have a 
national value set. 
Conclusions: Increasing use of EQ-5D is observed throughout CEE. The spread of health 
technology assessment activities in countries seems to be reflected in the number of EQ-5D 
studies. However, improvement in informed use and methodological quality of reporting is 
needed. In jurisdictions where no national value set is available, in order to ensure 
comparability we recommend to apply the most frequently used UK tariff. Regional 
collaboration between CEE countries should be strengthened. 
 
Keywords: EQ-5D, health-related quality of life, value sets, health technology assessment, 
cost-effectiveness analysis, Central and Eastern Europe 
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Introduction 
 
Over the past decade health technology assessment (HTA) has been implemented in most 
Central and Eastern European (CEE) countries based on methodologies of international 
standards [1]. These countries have formal HTA organisations involved in reimbursement 
decision making of health technologies. To support reimbursement decisions, cost-
effectiveness analyses, or rather cost-utility analyses, in which quality of life or quality-
adjusted life year (QALY) is the preferred outcome measure, are required in many CEE 
countries [2-8]. Currently in the Czech Republic, Hungary, Poland and Romania, health 
interventions are deemed to be generally accepted if their incremental cost per QALY gain is 
not greater than 3 times the countr\¶s GDP per capita [9,10,2].  
The EQ-5D is by far the most commonly used preference-based instrument to calculate  
utility scores in CEE [11]. The main advantages of EQ-5D are its widespread use, briefness 
and the simplicity of administration. Official language versions are available for all the 
national languages of CEE countries. On the contrary, only very limited data is available from 
CEE countries using other preference-based measures such as SF-6D [12-14] and Health 
Utilities Index (HUI) [15] or directly measured utilities such as time trade-off or standard 
gamble [16-19]. Of note, HUI has not been validated in the national languages of CEE 
countries with the exception of Austria.  
HTA bodies in the UK (National Institute for Health and Care Excellence, NICE) [20] and the 
US (Washington Panel on Cost-Effectiveness in Health & Medicine) [21] recommend using 
utilities obtained by indirect measures in cost-utility analyses. These recommendations were 
adopted by Hungary, Poland and Romania, which have included the EQ-5D as a preferred 
instrument in their HTA guidelines (Table 1) [2,4]. In Austria, the latest HTA guideline also 
recommends indirect methods of utility elicitation but without a specific recommendation of 
the EQ-5D [5]. In Slovakia, in contrast, direct methods are required [3], whilst in other CEE 
countries there is no preferred choice of instrument to derive utilities [5,6,22,8,7]. Little is 
known, however, about how far CEE countries have actually used the EQ-5D.  
Prior systematic reviews have been conducted on various fields related to the use of EQ-5D 
including psychometric properties of the measure (e.g. minimal clinically important 
difference or responsiveness to clinical change)[23-25], EQ-5D valuation studies [26] and a 
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number of prevalent disease areas [27-36]. Nonetheless, the real-life use of EQ-5D in terms of 
geographical regions and as a proxy to HTA has not been reviewed to date. 
The purpose of this study is, therefore, to systematically review the published literature on 
EQ-5D from selected CEE countries, namely Austria, Bulgaria, the Czech Republic, Hungary, 
Poland, Romania, Slovakia and Slovenia. Specifically, we aim to discuss the following issues:  
 What has been the growth and composition of the literature on the EQ-5D in CEE? 
 In which clinical areas has the EQ-5D been used in CEE? 
 What are decision-makers' guidance on the approach for estimating utilities and does 
the literature match these? 
 What is the quality of the studies and study reporting?  
 What could/should analysts do in situations where there is no national value set and 
what are the implications of the various options? 
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Methods 
 
EQ-5D 
The EQ-5D questionnaire is a descriptive system that focuses on five health dimensions: 
mobility, self-care, usual activities, pain/discomfort and anxiety/depression [37,38]. Three 
versions of the instrument have been developed: a 3-level (EQ-5D-3L), 5-level (EQ-5D-5L) 
and a youth version (EQ-5D-Y) for children and adolescents aged 7 to 12 years [39-42]. In the 
EQ-5D-3L, each dimension has three response categories (representing no problems, some 
problems and severe problems), whereas in the EQ-5D-5L, responses may be one of five 
levels of severity (no problems, slight problems, moderate problems, severe problems, 
extreme problems). EQ-5D index scores can be attached to each health state description by 
applying societal preference weights to the self-report provided by the respondent. A number 
of value sets have been developed based on preferences of the general population elicited 
using a direct method such as time trade-off and EQ-5D visual analogue scale. In addition to 
the descriptive self-classifier, the EQ-5D contains a 20 cm visual analogue scale (EQ VAS) 
ranging from 0 (worst imaginable health) to 100 (best imaginable health) along which the 
respondents rate their current health.  
 
Data collection 
We followed the PRISMA checklist for reporting systematic reviews in our study [43]. A 
database search was performed using MEDLINE via PubMed, EMBASE, Web of Science, 
CINAHL, PsycINFO and The Cochrane Library up to July 1, 2015. We also conducted a 
search of the EuroQol Group database to identify additional studies with EQ-5D. The search 
strategy used the combination of the following terms: (euroqol OR euro qol OR eq5d OR eq 
5d OR eq-5d) AND (Austria* OR Bulgaria* OR Hungar* OR Czech OR Poland OR Polish 
OR Romania* OR Slovak* OR Sloven*). Reference lists of articles identified through 
computerised search were also reviewed for relevant studies. Pooling their country expertise, 
the authors also hand searched for further papers from their own countries, which were 
published in journals not indexed in electronic databases. There were no language restrictions.  
Articles were included in this review if they met the following criteria: i) full-text published 
paper; ii) represented an original research; iii) the study population originated from Austria, 
Bulgaria, the Czech Republic, Hungary, Poland, Romania, Slovakia or Slovenia; and iv) the 
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article reported EQ-5D measurement (psychometric) properties or scores on the EQ-5D index 
or EQ VAS or percentage dimension scores from either the adult or paediatric population. 
When interim or multiple studies reported data on the same patient population, only one paper 
was included, preferably the one which had a larger sample size. Multi-country studies, where 
EQ-5D outcomes of the CEE countries were not reported separately from other countries, 
were excluded. 
Study abstracts that potentially met the inclusion criteria were identified, and full-text articles 
were retrieved for further review. Articles were assessed for eligibility by two independent 
investigators (F.R. and L.G.) with any disagreements resolved by discussion or a third 
researcher (M.P.). 
Experts from all countries under study were involved in the systematic discussion of the 
situation in their country, based on a common set of questions.  
 
Data extraction 
A Microsoft Excel spreadsheet was developed to collect data from the identified studies. This 
covered general characteristics of the papers (year of publication, language and funding 
source), methodological features of the study (method of data collection, design, setting and 
study year), characteristics of the study population (patients/general population, diagnosis and 
sample size), version of the questionnaire (EQ-5D-3L or EQ-5D-5L or EQ-5D-Y), tariffs 
used, mean EQ-5D index scores, mean EQ VAS scores, percentage dimension scores and 
total number of utilities (when EQ-5D index scores were stratified by subgroups, e.g. age, 
clinical types, severity) reported in the paper. Only participants who completed the EQ-5D 
were included in the sample size for studies. Diagnoses were classified according to the 
International Statistical Classification of Diseases and Related Health Problems 10th Revision 
(ICD-10) [44]. 
  
Results 
Search results 
Results of the study selection process and reasons for exclusions are detailed in Figure 1. The 
electronic search of databases identified 108 articles that fulfilled our predefined inclusion 
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criteria. An additional 35 papers were found through hand searching by the authors, resulting 
in a total of 143 papers. Two of them were large European multi-country studies that involved 
more than one CEE country [45,46]. Overall 152 reports on country level results were 
obtained: Austria (n=11) [47-57], Bulgaria (n=6) [45,46,58,59,13], Czech Republic (n=18) 
[60,61,45,46,62-66,20,67-74], Hungary (n=47) [11,75,76,45,77-93,14,94,18,95-116,12], 
Poland (n=51) [117,118,45,46,119-165], Romania (n=2) [45,46], Slovakia (n=3) [166-168] 
and Slovenia (n=14) [169-178,45,46,179,180].  
 
Characteristics of the studies 
Main study characteristics are displayed in Table 2. The first EQ-5D studies in CEE were 
published from Slovenia (2000) [170], Hungary (2001) [114], Austria and Poland (2003) 
[51,181], followed by Slovakia (2004) [168], the Czech Republic (2007) [70,71], Romania 
(2013) [45] and Bulgaria (2014) [13]. In the past 15 years, the number of publications has 
steadily increased in the region (Figure 2). Two-thirds of the studies were published in 
English (n=97; 68%) and all non-English papers had an English abstract. The largest number 
of non-English articles was observed in Hungary (n=18; 38%). However, the highest rate of 
non-English reports within a country was found in the Czech Republic (n=8; 44%). Overall 
105 (73%) studies stated the source of funding. The lack of a funding statement was most 
prevalent in Poland (n=22; 43%).  
The majority of the studies had a cross-sectional design (n=85; 59%). For longitudinal studies 
(n=55; 38%), the length of follow-up ranged from 10 days [171] to 9.5 years [51]. Registry-
based studies (n=3) were identified only in the Czech Republic and Hungary [77,64,74]. 
Almost all studies (n=126; 88%) were conducted as an on-site survey using a paper-based 
questionnaire. In addition, we identified six online or e-mail [11,80-82,182,173] and six postal 
surveys [86,95,53,123,174,180]. In three studies patients were permitted to complete the 
questionnaire at home and return it later [91,170,179]. 
Total sample size of all studies from the eight countries was 81,619 with Poland (39%) and 
Hungary (34%) representing the majority. Fifty-seven (40%) studies had a sample size of less 
than 100 and there were 20 (14%) studies involving more than 1000 participants. Studies of 
the two largest populations were a general population sample from Hungary (n=9,407) [80] 
and a group of chronic obstructive pulmonary disease patients (n=8,537) from Poland [145].  
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Population norms 
There were 14 studies (10%) that involved the general population. These were conducted in 
Bulgaria (n=1), Hungary (n=4), Poland (n=6) and Slovenia (n=3). Among these, we found 
representative population norms from Hungary, Poland and Slovenia 
[11,136,149,115,164,180]. Further, local population norm is available for the city of Burgas in 
Bulgaria [59]. 
 
Clinical areas 
Most studies were based on data from patient populations (n=116; 81%). A wide range of 
clinical areas were covered by the studies, of which diseases of the circulatory system (n=29; 
20%), nervous system (n=23; 16%), musculoskeletal system and connective tissue (n=21; 
15%), and endocrine, nutritional and metabolic conditions (n=20; 14%) were the most 
frequent (Figure 3). Hungary led in the number of musculoskeletal (n=13; 29%) and 
neurologic studies (n=12; 28%), Poland in cardiovascular (n=17; 33%), and 
nutritional/metabolic studies (n=9; 18%), and the Czech Republic in cardiovascular research 
(n=7; 39%). There were EQ-5D studies from all eight CEE countries in circulatory diseases. 
The most common diagnoses were ischaemic heart disease (n=14), diabetes (n=10), 
3DUNLQVRQ¶V GLVHDVH Q ), multiple sclerosis (n=8), chronic pain and rheumatoid arthritis 
(n=6 for both) (Figure 4). Four VWXGLHV DVVHVVHG QRWRQO\ WKHSDWLHQWV¶KHDOWK VWDWXVEXW WKH
FDUHJLYHUV¶DVZHOO[89,81,82,182].  
 
EQ-5D results: versions of questionnaire, methods of reporting and scores 
Eleven studies (8%) employed the EQ-5D-5L [46,65,88,97,77,81,82,130,164,160,165]. No 
articles reported results on the youth version of the questionnaire (EQ-5D-Y), possibly 
because the validation process of the CEE national language versions was only completed in 
May 2015. There were two studies from Hungary that administered the EQ-5D adult version 
on paediatric patients aged 6-17, due to the lack of validated Hungarian version of the EQ-
5D-Y [81,82].  
10 
 
A total of 112 (78%) studies reported EQ VAS scores. We found nine studies 
[134,147,140,141,159,129,117,118,127] that reported only EQ VAS results despite using the 
descriptive system and five other studies that applied only EQ VAS but not the descriptive 
system [150,137,125,158,159]. Further, in four studies only the descriptive system was 
administered without the EQ VAS [116,174,175,178].  
Out of the 104 (73%) studies that reported responses to the EQ-5D self-classification system, 
67 (47%) indicated the percentage of respondents across the five dimensions and 86 (60%) 
calculated an EQ-5D index score. Almost half of these studies applied the UK tariff (n=41, 
48% of 86 studies). Overall 27 (31% of 86 studies) did not specify which tariff was used to 
calculate the EQ-5D index score. Poland and Slovenia are the only CEE countries with their 
own national tariff [120,183,184]. In Hungary, Bulgaria and Romania, studies were mainly 
based only the UK value set, in Austria and the Czech Republic on the UK or European, and 
in Poland and Slovenia on the UK or available national value set.  
Total number of EQ-5D index scores reported using the EQ-5D from CEE was 542 and the 
majority was originated from Hungary (n=248; 46%), Poland (n=104; 19%) and the Czech 
Republic (n=93; 17%). Mean or median EQ-5D index and EQ VAS scores of studies varied 
widely and typically patient populations represented the lowest and general population the 
highest scores in most of the countries (Appendix).  
 
Discussion 
 
The growth and composition of the literature on the EQ-5D in CEE 
In this review, we identified 143 published EQ-5D studies in eight CEE countries from the 
past 15 years. The first publication on EQ-5D from CEE was dated 10 years after the 
development of the measure. Thereafter, however, has been an increasing trend in the number 
of published studies from CEE up to 2015 (Figure 2). The growth was the most striking in 
Hungary and Poland after 2007. For comparison, in August 2015, the EuroQol database 
contained the following number of studies from other countries: the UK (n=628), Spain 
(n=234), US (n=230), the Netherlands (n=228), and Germany (n=155) and Canada (n=98). 
Nonetheless, these are only approximate estimates, because as it is outlined in Figure 1, the 
records identified for each country in the EuroQol database can differ from the actual number 
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of studies meeting the inclusion criteria of this review. One reason for the lag of CEE behind 
North America, and Northern and Western Europe is that the first EQ-5D studies were 
published for these countries in the early 1990s, whereas for CEE not until the 2000s. This 
can be explained by the later introduction of requirements to demonstrate cost-effectiveness 
evidence for reimbursement decisions [185-187]. 
Clinical areas where EQ-5D is used in CEE 
In CEE, cardiovascular (20%), neurologic (16%), musculoskeletal (15%), and nutritional and 
metabolic diseases (14%) represented the four main fields of research in CEE. Interestingly, 
in spite of cancer being among the most frequent disease-specific applications of the EQ-5D 
[29], we found only four oncological studies from CEE: breast cancer [73], lymphoma, 
leukaemia and myeloma multiplex [70], bone metastases in breast cancer or myeloma 
multiplex [60] and bladder cancer [14].  
After reviewing these 143 papers from CEE, it is unclear why these four clinical areas have 
become the subject of most EQ-5D studies. The motivation in the background of many studies 
is not apparent, as 27% of the studies did not include a financial disclosure and 15% were 
non-funded studies. We assume that a higher-level strategy in topic selection for EQ-5D 
studies does not exist in CEE countries. Some patterns, however, can be identified that make a 
bridge between the clinical areas investigated and the funding received. In Hungary, for 
example, 75% of EQ-5D studies carried out in conditions of the nervous system (including 
ILYHRXWRI WKHVL[+XQJDULDQVWXGLHV LQ3DUNLQVRQ¶VGLVHDVHZHUHDW OHDVWSDUWO\ IXQGHGE\
government organisations. Thus, in Hungary 53% of all governmental sponsorship was 
directed to the field of neurological research. Similarly, in the Czech Republic, 57% of studies 
referred to diseases of the circulatory system and received funding from government 
organisations (50% of all governmental financed studies of the country). It seems therefore 
that neurological conditions in Hungary and cardiovascular diseases in the Czech Republic 
were priorities for state-funded EQ-5D research. On the other hand, no similar health policy 
strategy among projects funded by the EU or the EuroQol Group could be identified. From 
the latter two sources, mainly data collection for establishing country-specific population 
norms and various EQ-5D related methodological researches were financed in CEE. 
Considering all eight countries, the diseases that received the most funding from 
pharmaceutical or medical device companies and foundations were diabetes including 
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Only four studies assessed EQ-5D of caregivers; however, having a family member with a 
chronic illness may impose a substantial burden on the caregiver. In the recent years, the 
literature concerning this spillover effect has largely evolved, but this QALY loss is typically 
still not incorporated in cost-effectiveness analyses [188-191]. 
The distribution of clinical areas covered by the studies in CEE cannot be compared to other 
countries or regions due to the lack of such data. Between 2009 and 2013, over 6,800 EQ-5D 
studies have been registered [192]. Nevertheless, no sort order, such as ICD groups or 
individual diagnoses, is given for the total number of registrations, that hampers to produce a 
meaningful comparison with our data [192].  
Methodological deficiencies in studies 
Substantial heterogeneity was found in the quality of papers. Methodological deficiencies, 
such as the lack of reporting either EQ-5D index scores (40%) or EQ VAS scores (22%) and 
not stating which tariff was used (in the 31% of the studies that calculated EQ-5D index 
score), were the leading causes of poor quality. Some studies indicated recording only the EQ 
VAS but not the descriptive system [150,167,158,137,125,159]. In one study, the EQ VAS 
scale was modified to range from 0 to 10 [173]. Alternative scoring techniques occurred in 
some studies; for example, the ordinal numeric labels for the health state levels in the 
instrument (1-3 or 1-5) were treated as cardinal values that can be summed 
[51,90,95,163,54,116,126,131,65,171,173], which is a flawed concept because these numbers 
have no intrinsic arithmetic properties. Another study expressed the EQ-5D index score as a 
percentage [72], which can be misleading when considering the possible negative values. To 
overcome these methodological shortcomings, the standards outlined in the EQ-5D User 
Guide should be met [193]. Further, stating the period when the study was conducted (25%) 
and disclosing the source of financing (27%) were commonly missing in published studies. 
These are important points to improve methodological quality and the transferability of 
studies.  
Overall, 7% of studies were RCTs (Austria n=2, Hungary n=5, Poland n=2 and Slovakia 
n=1), which seems low considering the rate of RCTs to total number of EQ-5D studies 
registered globally between 2009 and 2013 (29% of some 6,800 studies) [192]. This might be 
partly explained by the fact that, according to the HTA guidelines in CEE countries, patient-
reported study data from clinical trials is not necessary for reimbursement submissions [1]. 
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Also, multi-country RCTs, in which no individual results of CEE countries were reported, 
were excluded from this review. 
 
Decision-makers' guidance on the approach for estimating utilities in CEE 
In countries such as Poland (n=51) and Hungary (n=47), where the most EQ-5D studies have 
been carried out within CEE, HTA bodies encourage the use of indirect methods, particularly 
the EQ-5D, to elicit utilities for economic evaluations in reimbursement applications (Table 1) 
[2,4]. In contrast, we have found very few published papers from the other six countries. In 
most of these countries, there is no preferred choice of instrument to assess utilities with the 
exception of Slovakia, where direct methods are recommended according to HTA guidelines, 
and Romania which suggests the EQ-5D based on UK and French recommendations [3,5,8,1]. 
Apparently, the inclusion of EQ-5D as a preferred instrument in national HTA guidelines 
plays a key role in promoting the use of EQ-5D.  
In all countries studied, pharmaceutical companies are required to submit quality of life data 
as well as cost-effectiveness or cost-utility analysis, when demanding reimbursement for new 
drugs (Table 1). Yet it is unclear how these results are used [194-196]. In the near future, 
given the developments of HTA, the use of health state utility evaluations as an aid to 
healthcare decision makers will probably sharply increase in CEE. However, to be relevant 
for health policy decisions, studies must be valid, comparable, reliable, relevant to the policy 
context and communicated to the appropriate decision makers.  
Up unto the end of 2013 more than 2,500 reimbursement decisions have been made in a group 
of selected CEE countries such as Poland, the Czech Republic, Hungary, Romania and 
Bulgaria[1]. In contrast the number of EQ-5D studies was merely 75 during this period. 
Transferring EQ-5D data from other jurisdictions seems to be the major source of the 
cost/QALY calculations and financing decision-making in CEE [9]. Nevertheless, in HTA 
guidelines of CEE countries, no guidance is provided as to how (and from which countries) to 
transfer EQ-5D results. Cost/QALY calculations based on EQ-5D results from other countries 
might be biased due to various methodological reasons (e.g. differences in tariffs, patient 
populations, response-scale heterogeneity etc.) [197,198]. Thus, more emphasis should be 
placed on generating locally-relevant data in the future. 
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What could/should analysts do in situations where there is no national value set and 
what are the implications of the various options?  
To date, only two CEE countries have their own national value sets: Poland and Slovenia. 
(Poland is not listed on the website of EuroQol (www.euroqol.org) as their tariff was not 
produced as a part of the EuroQol Group.) In Austria, the Czech Republic, Poland and 
Slovenia, different value sets have been used to calculate EQ-5D index scores (despite the fact 
that Poland and Slovenia have their own national tariffs). This has the drawback that it 
prevents a proper comparison between results of studies undertaken in the same country. In 
Hungary, in contrast, the UK value set was applied pragmatically in all studies including the 
population norm, which has been used as a reference in several studies to assess the utility 
loss of specific patient populations. $OWKRXJKXVLQJRWKHUFRXQWULHV¶YDOXHVHWVIRUHFRQRPLF
purposes is acceptable in the absence of local tariffs, it has weaknesses because variations in 
utility values assigned to the same EQ-5D health states can occur among countries [199-204]. 
By employing tariffs deriving from the population of another country, utility weights and 
QALY gains may represent different societal and even cultural values; thus, healthcare 
resource allocation decisions based on these estimates of QALYs gained may not reflect the 
societal preferences in the country of interest.  
We believe that in those countries, such as Hungary and the Czech Republic, where the 
number of studies is relatively high and clearly shows an increasing trend, the establishment 
of country-specific tariffs should be promoted. In practice, however, two major issues would 
remain unresolved, comparability between earlier and new studies and across countries. If all 
CEE countries developed their own value sets, the comparisons across the region will become 
more challenging because of the differences caused by the methodological variations in 
developing new value sets [197]. Therefore, when a country constructs its own value set (for 
the 3-level and/or the 5-level versions), we suggest presenting the results thereafter both with 
the new national and the UK tariffs ZKLFKKDVEHHQXVHGDVDNLQGRI³FRPPRQODQJXDJH´XS
to date to calculate the EQ-5D index score in the region. Results of earlier EQ-5D studies, 
wherever feasible, could be adapted by applying the new tariff as well. We believe that 
otherwise the loss of consistency and comparability across CEE countries largely outweighs 
the gain achieved with the more accurate utility values resulting from the application of 
different country-specific tariffs. In further studies in CEE countries with no national value 
set, we recommend the application of the UK tariff, which has been used in the largest 
number of studies in the region.  Further, similarly to the European value set, which was 
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developed in six countries including Finland, Germany, The Netherlands, Spain, Sweden and 
the UK [205], a common CEE EQ-5D tariff could be the first step of the collaboration 
between CEE countries. This would facilitate regional comparisons, and these are assumed to 
share some characteristics that might drive the health state valuations, a regional tariff would 
be more appropriate to be used for financial decisions until country-specific value sets are 
obtained.  
 
Conclusions 
Research activity with the EQ-5D is increasing in the CEE region; however, some clinical 
areas with high health and economic impact are understudied. Considerable variability can be 
observed between countries both in terms of the proliferation of use and the methodological 
quality of studies. Our results provide a basis to develop research agenda at the national level 
as well as for regional collaborations. Other countries may also learn from the experience 
from this review. First, late adopters, such as CEE, are those that indeed determine the 
worldwide spread of the EQ-5D. Second, if payers and policymakers in a country are fully 
committed to cost-effectiveness, they are more likely to take the extra burden of appropriate 
measurement of health outcomes. Third, as transferring utilities from one country to another 
remains the major source of utilities, there is a need for some translational guidelines for 
taking utility estimates and adapting them for local use.  
 
 
   
16 
 
Table 1 Preferred outcomes in the pharmacoeconomic guidelines in CEE countries  
  
Preferred analytical 
technique 
Preferred 
outcome 
measure 
Preferred method to derive utility Reference 
Austria CMA, CEA, CUA  
Depends on 
research 
question 
Preference-based, indirect methods  
Methodenhandbuch für 
Health Technology Assessment 
Version 1.2012 (2012)[5] 
Bulgaria CEA/CUA QoL, QALY Quality of life measures (not specified) 
Methodological guideline for presentation 
of documents for evaluation of the 
efficacy, safety and pharmacoeconomic 
indicators of medicinal products for 
application for inclusion into the Positive 
Drug List (2015) [22] 
Czech 
Republic not recommended QoL, QALY Disease-specific or generic questionnaires 
Czech Pharmacoeconomic Society (2009) 
[8] 
Hungary CMA, CEA, CUA  QoL, QALY 
Using a preference-based multidimensional health related 
quality of life questionnaire (EQ-5D, Health Utilities Index, a 
Quality of Well-Being Scale or Years of Healthy Life) is 
recommended in the first place.  
Ministry of Human Resources, Hungary: 
Technical Guideline for the Making of 
Health-Economic Analyses (2013) [2] 
Poland CEA, CUA, CCA QoL, QALY 
The preference measurement for the purposes of utility 
assessment is possible by using direct or indirect preference 
measuring methods. It is recommended to use indirect methods 
for preference measurement ± validated questionnaires in 
Polish. While measuring preferences with the EQ-5D 
questionnaire, it is advised to use the Polish utility standard set 
obtained by means of the TTO method. 
Agency for Health Technology 
Assessment. Guidelines for conducting 
Health Technology Assessment (HTA). 
Version 2.1. Warsaw (2009) [4] 
Romania CEA/CUA QALY Having benchmarking NICE/SMC/AWMSG recommendations 
report EQ-5D can be considered preferred Gulácsi et al. 2014 [1] 
Slovakia 
CUA if the treatment has an 
impact on health-related QoL 
that is significant to the 
patient or if there are 
multiple patient-relevant 
clinical outcome parameters 
QoL, QALY TTO or SG (VAS)  Ministry of Health, Slovakia (2008) [3] 
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expressed in different units.  
Slovenia CEA/CUA/CMA/CA 
QALY 
(intermediate 
outcomes can 
be accepted, 
such as blood 
pressure, 
cholesterol, 
glycosylated 
hemoglobin, 
and 
hospitalization
) 
There is no preferred instrument. Assembly of the Health Insurance Institute (2010) [7] 
AWMSG = All Wales Medicines Strategy Group, CA = cost analysis, CCA = cost consequences analysis, CEA = cost-effectiveness analysis, CMA = cost minimisation 
analysis, CUA = cost-utility analysis, NICE = National Institute for Health and Care Excellence, QoL = quality of life, QALY = quality adjusted life year, SMC = Scottish 
Medicines Consortium, SG = standard gamble, TTO = time trade-off, VAS = visual analogue scale 
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Table 2 Characteristics of the studies 
Variables 
Number of country-level results (n=152) 
(includes two multi-country studies involving 5 and 6 
CEE countries, respectively) [45,46] 
Number of 
studies 
(n=143) 
A
us
tr
ia
 
Bu
lg
a
ri
a 
C
ze
ch
 
R
ep
ub
lic
 
H
u
n
ga
ry
 
Po
la
n
d 
R
om
a
n
ia
 
Sl
ov
a
ki
a 
Sl
ov
en
ia
 
TO
TA
L
 
Pr
o
po
rt
io
n
 
Total number of studies 11 6 18 47 51 2 3 14 143 100% 
English 10 5 10 29 35 2 2 13 97 68% 
Other language 1 1 8 18 16 0 1 1 46 32% 
Publication year of the first 
EQ-5D study 2003 2014 2007 2001 2003 2013 2004 2000 - - 
Study sample*                     
Population-based: general 
population 0 1 0 4 6 0 0 3 14 10% 
Population-based: elderly 2 0 0 0 6 0 0 0 8 6% 
Population-based: other 1 1 1 0 2 0 0 3 8 6% 
Not population-based 8 4 17 43 41 2 3 12 116 81% 
Total sample size of studies 3483 2488 4047 28115 
3198
8 1043 1423 9032 81619   
<50 0 1 4 8 8 0 2 1 24 17% 
50-99 3 0 2 14 14 0 0 0 33 23% 
100-499 6 2 11 19 17 0 0 7 55 38% 
500-999 1 2 1 2 5 2 0 2 11 8% 
 1 1 0 4 7 0 1 4 20 14% 
Study design                 
  
  
RCT 2 0 0 5 2 0 1 0 10 7% 
nonrandomized clinical trial 0 0 0 1 3 0 0 0 4 3% 
prospective cohort 4 0 11 8 8 0 2 5 38 27% 
retrospective cohort 1 0 0 1 1 0 0 0 3 2% 
case-control 0 0 0 0 2 0 0 0 2 1% 
cross-sectional 4 6 7 31 35 2 0 9 85 59% 
other 0 0 0 1 0 0 0 0 1 1% 
Method of data collection*                 
  
  
On-site 10 5 18 40 50 2 3 7 126 88% 
Internet-based / e-mail 0 1 0 4 0 0 0 1 6 4% 
Postal survey 1 0 0 2 1 0 0 2 6 4% 
Take home survey 0 0 0 1 0 0 0 2 3 2% 
Telephone interview 0 0 0 0 0 0 0 2 2 1% 
Setting                 
  
  
single centre 6 0 10 14 27 0 1 5 63 44% 
multicentre 3 4 6 24 15 2 1 4 50 35% 
patient registry 0 0 2 1 0 0 0 0 3 2% 
N/A 2 2 0 6 7 0 0 5 22 15% 
NR 0 0 0 2 2 0 1 0 5 3% 
Study year(s)                  
  
  
Reported 11 6 16 33 33 2 2 13 107 75% 
Not reported 0 0 2 14 18 0 1 1 36 25% 
EQ-5D                 
  
  
Used EQ-5D-5L 0 1 2 5 5 1 0 1 11 8% 
Reported dimension percentage 
scores 5 2 6 21 27 0 0 6 67 47% 
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Reported EQ VAS results 6 5 14 38 46 2 2 8 112 78% 
Reported results on EQ-5D 
descriptive system or 
calculated index score 8 4 16 44 30 1 0 10 104 73% 
Reported EQ-5D index score 6 5 15 42 17 2 1 7 86 60% 
Reported tariff used* 3 4 7 30 17 2 0 5 59§ 69% 
UK§§ 2 4 3 30 6 2 0 3 41§ 48% 
Polish 0 0 0 0 12 0 0 0 12§ 14% 
Slovenian 0 0 0 0 0 0 0 2 2§ 2% 
European 1 0 4 1 0 0 0 0 6§ 7% 
US 0 1 0 1 0 0 0 0 2§ 2% 
Tariff not specified 3 1 8 12 0 0 1 2 27§ 31% 
Total number of EQ-5D 
index scores  62 22 93 248 104 2 3 8 542 - 
Funding source reported*                  105 73% 
European Union 2 2 1 5 0 0 1 1 12 8% 
EuroQol Group 0 0 0 0 5 0 0 0 5 3% 
Foundation 1 0 0 10 0 0 0 0 11 8% 
Government organisation 2 1 8 17 3 0 0 0 31 22% 
University 0 0 2 0 4 0 0 0 6 4% 
Pharma/device company 4 1 4 5 5 1 1 2 23 16% 
Other 3 1 0 1 2 0 0 2 9 6% 
Not specified 0 0 2 1 0 0 0 0 3 2% 
None 0 1 1 11 12 1 0 4 21 15% 
Funding not stated 2 1 2 5 22 0 1 5 38 27% 
ICD-10 = International Statistical Classification of Diseases and Related Health Problems 10th Revision; N/A = 
not applicable; NR = not reported; RCT = randomised controlled trial 
* One study may refer to more than one subgroup within the following categories: study sample, methods of data 
collection, tariffs used and funding source.   
§ Percentage indicates the rate to the total number of studies that estimated EQ-5D utility score (n=86). 
§§ All studies from Bulgaria, Hungary and Romania employed the UK tariff but in some studies other tariffs 
were as well applied together with the UK one.  
20 
 
Figure legends 
 
Figure 1 PRISMA flowchart of the study selection  
 
Searched: July 1, 2015.  
* Literature search was conducted on a country basis; thus, the total number of studies is slightly higher than the 
real number of studies. 
** 7RWDOQXPEHURIVWXGLHVLQWKLVURZLVQRWHTXDOWRWKHVXPRIWKHµFRXQWU\FROXPQV¶EHFDXVHRQHVWXG\
included 6 and another 5 CEE countries [45,46]. 
 
 
Figure 2 Number of EQ-5D studies published in CEE countries from 2000 onwards 
 
CEE ± Central and Eastern Europe 
 
Figure 3 ICD-10 classification of the studies 
One study may refer to more than one ICD-10 group. The sum of percentages is less than 100% as the 
percentages indicate the proportion of a given ICD-10 group out of the total number of studies including 
population-based studies.  
 
Figure 4 Most common diagnoses/clinical areas among the studies 
The size of bubbles refer to the total number of patients of studies in a given diagnosis/disease group (i.e.  
the numbers in brackets after diagnoses). For studies that assessed EQ-5D in various patients groups, only the 
number of patients with the diagnosis/or clinical area of interest is included in this figure.   
COPD = chronic obstructive pulmonary disease; PAOD = peripheral arterial occlusive disease   
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Appendix - Lowest mean EQ-5D index and EQ VAS scores by country 
 
EQ-5D 
index score Diagnosis Reference EQ VAS Diagnosis Reference 
Austria 0.11 multiple sclerosis Expanded Disability Status Scale > 6.5 [57] 38.00 
multiple sclerosis Expanded Disability 
Status Scale > 6.5 [57] 
Bulgaria 0.63 diabetes [13] 58.00 diabetes [13] 
Czech 
Republic 0.16 rheumatoid arthritis before biological therapy [74] 51.00 neuropathic pain [68] 
Hungary 0.02 rheumatoid arthritis with Health Assessment Questionnaire Disability Index>2.6 [113] 30.00 secondary dystonia [88] 
Poland -0.03 stroke, Modified Rankin Scale 5 [160] 22.50 low back pain or sciatic nerve pain [125] 
Romania 0.75 coronary heart disease [45] 59.15 coronary heart disease [46] 
Slovakia 0.52 degenerative lumbar spine preoperatively [166] 51.00 critical limb ischaemia [167] 
Slovenia 0.54 multiple sclerosis [176] 49.20 multiple sclerosis [176] 
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